Psychological impact of genetic testing for
Huntington's disease: an update of the literature
Bettina Meisera, Stewart Dunnb
a Hereditary Cancer Clinic, Prince of Wales Hospital, Randwick,
NSW 2031, Sydney, Australia, b Department of Psychological Medicine,
University of Sydney, NSW 2006, Sydney, Australia
Correspondence to: Bettina Meiser b.meiser@unsw.edu.au
Accepted 21 March 2000
Abstract
Genetic testing has been available for Huntington's disease for longer
than any other adult onset genetic disorder. The discovery of the
genetic mutation causing Huntington's disease made possible the use
of predictive testing to identify currently unaffected carriers.
Concerns have been raised that predictive testing may lead to an increase
in deaths by suicide among identified carriers, and these concerns set in
motion research to assess the psychological impact of predictive testing
for Huntington's disease.
This review article provides an overview of the literature and draws
implications for clinical practice.
About 10%-20% of people at risk request testing when approached by
registries or testing centres. Most of the evidence suggests that non-
carriers and carriers differ significantly in terms of short term, but not
long term, general psychological distress. Adjustment to results was
found to depend more on psychological adjustment before testing than
the testing result itself.
Although risk factors for psychological sequelae have been identified,
few adverse events have been described and no obvious
contraindications for testing people at risk have been identified. The
psychological impact of testing may depend on whether testing was
based on linkage analysis or mutation detection.
Cohorts enrolled in mutation detection programmes have higher levels
of depression before and after testing, compared with people who
sought genetic testing when linkage analysis was available.
There is evidence that people who choose to be tested are
psychologically selected for a favourable response to testing. The
impact of testing on people in settings where less intensive
counselling protocols and eligibility criteria are used is unknown,
and genetic testing is therefore best offered as part of comprehensive
specialist counselling.
(J Neurol Neurosurg Psychiatry 2000;69:574-578)
Huntington's disease; psychological adjustment; genetic testing
Introduction
The frequency of Huntington's disease in populations of European
descent is between three and seven affected people per 100 000
population.1 The mean age of onset of Huntington's disease is
40 years, with a mean duration of 15 years.1
About 98% of patients with Huntington's disease have an expansion
of a trinucleotide (CAG) repeat on the Huntington gene.1 No medical
treatments to delay onset of disease or prophylactic strategies are
available.
The discovery of a genetic marker for Huntington's disease in 1983
made possible the use of linkage analysis to identify currently un-
affected carriers with a sensitivity of about 96%-99%.2 Linkage
analysis takes advantage of the spatial proximity of a marker and
a mutation and requires blood samples from both affected and un-
affected family members over several generations. The nature of
linkage analysis is probabilistic, because genetic recombination can
occur between markers and the gene during meiosis.
Most carriers and non-carriers were given risk estimates of 90% or
more and 10% or less respectively, reflecting the relatively low
accuracy of these earlier linkage studies. Since identification of the
responsible gene mutation in 1993,3 direct mutation detection methods
have been applied, leading to highly accurate predictive testing with
a sensitivity and specificity of virtually 100%.
Compared with other dominantly inherited genetic traits leading to
adult onset disorders, predictive testing for Huntington's disease has
been offered for the longest time.4 Carriers will definitely get the
disease that is, Huntington's disease confers 100% penetrance, which
refers to the proportion of carriers of a genetic alteration who will
manifest the effects of it and is equivalent to lifetime incidence.
Non-carriers definitely will not develop the disease.
When linkage analysis first became available, concerns were raised
over the possibility of predictive testing leading to an increase in
deaths by suicide among identified carriers. Suicide has long been
recognised as a serious consequence of Huntington's disease.
One carefully designed study reports a fourfold increase in the suicide
rate among people affected compared with the rate of the general
white population in the United States.5 Attitudinal surveys of people
at risk suggest that between 11% and 33% considered suicide a
possible response in the future.6
These data highlighted the need for research to identify predictors of
depression and suicidal intention in people entering predictive testing
programmes for Huntington's disease. The identification of the genetic
marker prompted a considerable amount of research on attitudes to,
and the psychological impact of, testing for the disease.
Attitudes to genetic testing for Huntington's disease
Methodological aspects and major findings of intention to test surveys
of people at risk carried out since the genetic marker was identified,
but before mutation analysis became available, are summarised in
table 1.
Between 40% and 79% of people at risk of developing Huntington's
disease reported intention to use the test. Interest in genetic testing
was found to be negatively associated with being married, and
positively correlated with the number of affected relatives and earlier
parental age of onset of Huntington's disease.6
The most commonly reported reasons for wanting to be tested were:
to be certain, to plan for the future, and to inform children.6 13
Data on actual uptake of testing suggest that uptake has been much
lower than suggested by attitudinal surveys. The percentage of people
at risk who requested testing when approached by registries or testing
centres varied from 9% in Wales, 10% in Indiana, 16% in the Manchester
area, to 20% in the Vancouver area.14
On the basis of the relatively low rate of uptake, it is likely that people
who chose to be tested are not representative of the Huntington's
disease population as a whole.15
People who decide to have the test are more likely to have higher
educational levels than the general population, and women tend to be
overrepresented,16 possibly reflecting women's traditionally greater
involvement in reproductive decisions or concern for existing children.17
Self-selection for favourable psychological response.
Several studies have provided evidence that people who choose to
be tested are psychologically selected for a favourable response to
testing. People who reported being at risk of suicide or anticipated
feeling depressed should the result be positive were significantly less
likely to want the test, compared with those not anticipating suicidal
or depressive feelings.6 9
The most commonly reported reasons for choosing not to have the
test related to the emotional and psychological consequences of a
positive test result such as fear of searching for symptoms and of
losing what hope could be retained.14
Other reasons for choosing not be tested were: increased risk to children
if found to be a carrier, absence of an effective cure, and potential loss
of health insurance.18
Compared with test recipients, people who declined testing were found
to be significantly more depressed and pessimistic.19 They were more
likely to expect to be carriers and anticipated more negative effects
from a positive result.19
Interestingly, people who declined were more likely to have learned
about their being at risk for Huntington's disease during adolescence,
rather than adulthood.19
Studies that compared psychological characteristics of people who had
enrolled in a linkage testing programme with those of the general
population found that psychological adjustment was comparable.17
However, people at risk were found to be more resourceful than the
general population.17
Mean anxiety and depression scores were found to be lower than means
for the general population, and test applicants had significantly higher
ego strength and were more socially extroverted.20
The evidence on self selection for a favourable response of people who
choose to have the test suggests that findings of studies on the
psychological impact of genetic testing for Huntington's disease may not
be generalisable to the population of people at risk of Huntington's
disease at large.
It has been suggested that those who are best equipped emotionally
to deal with the information opt for genetic testing.21 Alternatively, it
is possible that those who are psychologically more vulnerable do not
follow through the typically rigorous counselling and testing protocols.
Generalisability to settings where less intensive counselling protocols
and eligibility criteria are used is also limited, given that all psychological
impact studies reviewed were conducted as part of carefully designed
research programmes with comprehensive counselling.4 People with
less ego strength might have experienced considerable psychological
support through these often extensive programmes of counselling
before and after testing.
Differences in impact of testing between linkage analysis
and mutation detection
There is evidence that cohorts enrolled in direct testing protocols since
1993 have higher levels of depression before testing, compared with
people who sought genetic testing when linkage analysis was available.22
The psychological impact of testing may depend on whether testing
was based on linkage analysis or mutation detection.
Published studies include people tested by linkage,23 or mutation
detection, or a combination of both. Only one study permits a comparison
of the impact of different testing strategies.24 People tested by
mutation detection had higher depression scores 12 months after
disclosure compared with those tested by linkage.24 Several reasons
for the differences in psychological adjustment between the cohorts
have been suggested.
People who present for linkage testing may have had greater social
support before testing than those who do not have "to orchestrate
a family-wide effort to collect the blood samples required for Huntington's
disease linkage testing".24 Alternatively, the need to call on other
family members for participation in linkage testing might lead to improved
family communication and hence support.
Finally, the risk information presented during genetic counselling within
the context of linkage testing may account for the effect.24 Carriers
may have been consoled by knowing that there is a 1% chance that
they are not carriers,24 thereby providing increased scope for optimism
bias25 and its protective effects on mental health.26
Psychological impact of genetic testing for Huntington's disease
Table 2 presents a summary of methodological aspects and major findings
of prospective studies that used standardised measures of psychological
outcome and evaluated the psychological impact of genetic testing for
Huntington's disease.23 27
The table indicates which studies were based on linkage and which on
mutation analysis and presents results of significance tests between
carriers and non-carriers 7-10 days and 12 months after disclosure. For
ease of comprehension, people who underwent linkage analysis and
received increased risk results will be referred to as carriers and those
with decreased risk results as non-carriers.
Carriers and non-carriers differed significantly on all psychological outcome
measures at the 7-10 days, but not the 6 months and 12 months of follow
up.23 28 However, the study based on the largest sample size to date
measured hopelessness as a dimension of particular relevance to the
population of people at risk and found that differences between carriers
and non-carriers may persist long term.24 This finding raises some concern
about this particular population, given that hopelessness has been
identified as a predictor of suicide.29
The analysis of scores before, compared with after, receiving the test result
(results not shown in table 2) indicates that psychological adjustment of
non-carriers either tends to be unaltered24 28 or improves after receipt of
the result.23 27 Some studies found no significant changes from baseline
on any follow up measures for carriers,23 24 27 whereas others found
short term increases in hopelessness.
One study used a control group design and showed that people at risk who
did not receive a genetic testing result had higher scores for depression
and lower scores for wellbeing at the 12 month follow up, compared with
both carriers and non-carriers.23
The authors conclude that receiving a test result leads to psychological
benefits, even if it indicates carrier status, by reducing uncertainty and
providing an opportunity for appropriate planning.
Baseline levels of depression or hopelessness (rather than the test result
itself) were found to be the best predictors of levels of hopelessness
and intrusive thoughts after disclosure.24 30 People who were married,
had no children, and were closer to their estimated ages of onset of
Huntington's disease were found to be less well adjusted at all times.24
An unexpected finding was that a small proportion of non-carriers who
received a low risk result experienced serious difficulties in coping with
their new genetic status.31 In depth interviews showed that having
made irreversible decisions based on the belief that they would develop
Huntington's disease or overly optimistic expectations of the positive
effects of a decreased risk were contributing factors.
Survivor guiltthat is, guilt feelings relative to other family members who
tested positive or those already affected by Huntington's disease, were
also found.31
IMPACT ON PARTNERS OF PEOPLE UNDERGOING GENETIC TESTING
Tibben et al also followed up partners of people undergoing genetic
testing, and found that carriers' partners showed the same course of
distress as carriers.32
Compared with non-carriers' partners, carriers' partners had significantly
higher levels of psychological distress 1 week, 6 months, and 3 years
after disclosure.32
Having children was an additional psychological risk factor for carriers'
partners, who showed significantly higher scores on all psychological
outcome measures both short and long term, compared with carriers'
partners without children.32
These findings are similar to those of Quaid and Wesson33 and indicate
that genetic testing for Huntington's disease has significant effects on
partners of carriers, suggesting the need to include partners more
comprehensively in psychological assessments.35
Conclusion
Most of the evidence on the psychological impact of testing for Huntington's
disease suggests that non-carriers and carriers differ significantly in short
term, but not long term, general psychological distress. Carriers show
either no changes from psychological adjustment before testing23 24 27
or only short term increases in hopelessness.28 Adjustment to results
was found to depend more on psychological adjustment before testing
than the testing result itself.24 27 32
Although risk factors have been identified,24 36 few adverse events have
been described,36-38 and no obvious contraindications for testing have
been identified.24
The impact of testing on people in settings where less intensive counselling
protocols and eligibility criteria are used is unknown, and genetic testing
is therefore best offered as part of comprehensive specialist counselling
.
There is evidence that people who choose to be tested are psychologically
selected for a favourable response to testing. Given the potential psychological
sequelae of genetic testing in less well adjusted people, it is advisable to
routinely assess levels of depression or hopelessness with formal assessment
tools.29 People with high levels of depression or hopelessness may benefit
from referral to liaison staff with expertise in psychiatry or clinical psychology
before decision making about genetic testing.
Acknowledgements
BM is supported by Project Grant No 970929 from the National Health and
Medical Research Council of Australia. We thank the reviewers for their
valuable suggestions.